Insider sales are routine and immaterial. The strong Q1 results, plus $750M buyback authorization, support the stock. No action warranted.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $46.10entry
- T+1 · 6mo ago +4.45%α +3.62% · $48.15
- T+5 · 6mo ago +11.26%α +9.76% · $51.29
- T+20 · 6mo ago +11.94%α +8.80% · $51.60
- T+60 · 4mo ago +15.04%α +12.93% · $53.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Exelixis directors sold a combined $3.12M in open-market transactions following a strong Q1 2026 earnings beat (revenue +10%, EPS +44% YoY). The CEO gifted shares with no cash value. Total sales represent only 0.027% of market cap, well below materiality thresholds.
Key Financial Metrics
Key Facts
- Director George Poste sold 60,000 shares for $2.74M on May 7
- Director Mary Beckerle sold 7,712 shares for $374K on May 7
- CEO Michael Morrissey gifted 109,676 shares (no cash value) on May 6
- Q1 2026 earnings beat: GAAP EPS $0.79 vs $0.55 YoY, revenue $610.8M vs $555.4M
- Sales represent 0.027% of Exelixis's $11.6B market cap
Financial Impact
$3.12M in open-market sales, trivial relative to $11.6B market cap
Risk Factors
- Further insider selling above 0.5% of market cap would be more concerning
- Zanzalintinib pivotal data and FDA decision (December 2026) are key catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EXEL-1778281456308 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20267d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers